Letters to the EditorInterval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome)
References (5)
- et al.
Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review
Gastroenterology
(1993) - et al.
Hereditary non-polyposis colorectal cancer-morphologies, genes and mutations
Mutat Res
(1994)
Cited by (200)
Hereditary nonpolyposis CRC
2021, Foundations of Colorectal CancerNo Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies
2018, GastroenterologyCitation Excerpt :In 1990, the International Collaborative Group on HNPCC (now International Society for Gastrointestinal Hereditary Tumours, InSiGHT) recommended a surveillance interval of 2 to 3 years.5 However, a few years later, reports appeared describing patients who seemed to have developed a cancer within 2 to 3 years after a normal colonoscopy.20 Other studies also indicated that the adenoma-carcinoma sequence in LS might be accelerated.21–23
Surveillance of patients with hereditary gastrointestinal cancer syndromes
2016, Best Practice and Research: Clinical GastroenterologyCitation Excerpt :This improvement in the outcome is secondary to the identification and resection of colorectal polyps, and early detection of CRC. While the precise interval between surveillance colonoscopies is not well established, based on the fact that CRC have been observed within 2–3 years after colonoscopy, it is widely accepted to perform a colonoscopy every 1–2 years starting at the age of 20–25 years [21,22]. Prophylactic colectomy is not recommended in LS patients who have not developed CRC.
Colonoscopies for colorectal cancer screening
2014, Gastroenterologia y HepatologiaScreening and Management of Lynch Syndrome: The Chinese Experience
2023, Clinics in Colon and Rectal SurgeryColorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium
2022, Hereditary Cancer in Clinical Practice